ARGENX SE

Argenx SE: latest stock, market cap, and why investors should watch global economic releases and ECB policy for biotech insights.

Argenx SE fuels growth with AI‑driven BenchSci partnership, 18‑quarter sales momentum, and active investor outreach—pioneering next‑gen antibody therapies.

Argenx’s Phase‑III study of Efgartigimod shows significant muscle‑strength gains for autoimmune myositis, boosting investor confidence and paving the way for regulatory filings.

Argenx’s Q2 2026 results surge 60% as Vyvgart dominates sales, driving revenue to $1.52B and EPS to $7.32, with future pipeline readouts poised to broaden growth.

Argenx SE’s “Overweight” upgrade by Barclays highlights its 5,685% decade‑long growth, strong biotech pipeline, and resilience amid European market volatility.

Argenx SE, a leading biotechnology company, has reported impressive half-year financial results, exceeding market expectations with a GAAP EPS of $6.32 and revenue of $1.74 billion.

Argenx SE is preparing to release its financial results, highlighting the company’s ongoing commitment to advancing healthcare through innovative antibody-based therapies in the biotechnology industry.

Argenx SE, a biotechnology company, is making significant strides in treating severe autoimmune diseases and cancer with its innovative antibody-based therapies, including a promising candidate set to enter a registrational trial for Congenital Myas…

Argenx SE has secured European Commission approval for its innovative VYVGART subcutaneous injection, marking a significant milestone in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Argenx SE’s treatment VYVGART has received a positive opinion from the European CHMP, paving the way for potential approval and marking a significant milestone in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).